ARTICLE | Clinical News
Axalimogene filolisbac regulatory update
July 25, 2016 7:00 AM UTC
EMA classified Advaxis’ axalimogene filolisbac as an advanced therapy medicinal product (ATMP). The live Listeria monocytogenes-based immunotherapy expressing E7 transforming protein ( Human papilloma...